Discussion
High levels of anti-drug antibodies can reduce the availability of Myozyme (alglucosidase alfa) and the amount of the therapy that reaches cells in patients with classic infantile Pompe disease, a study found. Myozyme, the first enzyme replacement therapy (ERT) approved for Pompe disease, is sold as Lumyizyme…